EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Enhanced Antitumor Efficacy of 225Ac-NM600 Compared to 177Lu-NM600 in Prostate Cancer Models

Carolina A Ferreira, Hemanth K Potluri, Ahmed A Tantawy, Christopher F Massey, Joseph J Grudzinski, Amanda M Carston, Nathan B Clemons, Malick Bio Idrissou, Anna S Thickens, Zachary T Rosenkrans, Cynthia Choi, Caroline P Kerr und 8 weitere

International Journal of Radiation Oncology*Biology*Physics · 2026

DOI: 10.1016/j.ijrobp.2025.09.072 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026. Verfasst von Carolina A Ferreira und 19 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Radiology, Pharmacology and Toxicology and Biomedical Engineering, Michigan State University, East Lansing, Michigan. Hauptthemen laut MEDLINE: Lutetium, Radioisotopes, Actinium, Radiopharmaceuticals. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Many men with prostate cancer (PCa) develop metastatic castration-resistant PCa (mCRPC) after current treatment, which has a death rate of more than 50%. Although many approaches target mCRPC and show promising results, mCRPC is still incurable. Therefore, we aimed to investigate the efficacy and dosimetry of α (225Ac) versus β (177Lu) radiopharmaceutical therapy using NM600 in murine PCa models. METHODS AND MATERIALS: NM600 was radiolabeled with 177Lu and 225Ac for radiopharmaceutical therapy studies in immunocompetent mice. Single-photon emission computed tomography (SPECT)/CT imaging was conducted on syngeneic Myc-CaP and TRAMP-C1 PCa mouse models administered 7.4 MBq of 177Lu-NM600 in the tail vein. We calculated the dosimetry of 177Lu-NM600 therapy using SPECT/CT imaging and biodistribution data. Complete blood count, comprehensive metabolic panel, and histology analysis were carried out to assess toxicity in Myc-CaP and TRAMP-C1-beering mice (n = 9), which were given 5.55 (low injected activity [IA]) or 18.5 MBq (high IA) of 177Lu-NM600, and 7.4 (low IA) or 18.5 KBq (high IA) of 225Ac-NM600. Finally, the overall survival and tumor growth rate were monitored periodically for all groups. RESULTS: Both 225Ac/177Lu-NM600 demonstrated tumor-specific uptake and retention. 225Ac-NM600 exhibited superior antitumor effects and significantly improved overall survival compared to 177Lu-NM600 at similar doses. The enhanced efficacy of 225Ac-NM600 was attributed to its higher relative biological effectiveness. Toxicity studies revealed transient, dose-dependent hematological changes for both agents, with no significant long-term adverse effects. CONCLUSIONS: 225Ac-NM600 demonstrated enhanced antitumor efficacy compared to 177Lu-NM600 in murine PCa models, with a favorable toxicity profile. These outcomes reveal a strong rationale for further developing α-emitting radiopharmaceutical therapy agents for PCa treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LutetiumRadioisotopesActiniumRadiopharmaceuticalsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsAnimalsMaleMiceTissue DistributionSingle Photon Emission Computed Tomography Computed TomographyCell Line, TumorDisease Models, Animal

Substanzen

LutetiumRadioisotopesLutetium-177ActiniumRadiopharmaceuticalsActinium-225

Autor:innen und Institutionen

  • Departments of Radiology, Pharmacology and Toxicology and Biomedical Engineering, Michigan State University, East Lansing, Michigan.
  • Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
  • Comparative Medicine and Integrative Biology, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan.
  • Departments of Medical Physics and Radiology, University of Wisconsin-Madison, Madison, Wisconsin.
  • Pharmaceutical Sciences Program, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin.
  • Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin.

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NIGMS NIH HHS
  • National Cancer Institute
  • U.S. Department of Defense

Zitieren

APA

Ferreira, C. A., Potluri, H. K., Tantawy, A. A., Massey, C. F., Grudzinski, J. J., Carston, A. M., Clemons, N. B., Idrissou, M. B., Thickens, A. S., Rosenkrans, Z. T., Choi, C., Kerr, C. P., Pinchuk, A. N., Kwon, O., Jeffery, J. J., Bednarz, B. P., Morris, Z. S., Weichert, J. P., McNeel, D. G., & Hernandez, R. (2026). Enhanced Antitumor Efficacy of 225Ac-NM600 Compared to 177Lu-NM600 in Prostate Cancer Models. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.09.072

Vancouver

Ferreira CA, Potluri HK, Tantawy AA, Massey CF, Grudzinski JJ, Carston AM, et al. Enhanced Antitumor Efficacy of 225Ac-NM600 Compared to 177Lu-NM600 in Prostate Cancer Models. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2025.09.072

BibTeX
@article{Ferreira2026,
  author = {Ferreira, Carolina A and Potluri, Hemanth K and Tantawy, Ahmed A and Massey, Christopher F and Grudzinski, Joseph J and Carston, Amanda M and Clemons, Nathan B and Idrissou, Malick Bio and Thickens, Anna S and Rosenkrans, Zachary T and Choi, Cynthia and Kerr, Caroline P and Pinchuk, Anatoly N and Kwon, Ohyun and Jeffery, Justin J and Bednarz, Bryan P and Morris, Zachary S and Weichert, Jamey P and McNeel, Douglas G and Hernandez, Reinier},
  title = {Enhanced Antitumor Efficacy of 225Ac-NM600 Compared to 177Lu-NM600 in Prostate Cancer Models},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  doi = {10.1016/j.ijrobp.2025.09.072}
}
Kostenlos starten →